Compound preparation of valvciclovir HCL and Pidotimod

A technology of valaciclovir hydrochloride and pidotimod, which is applied in the direction of antiviral agents, dipeptide components, active components of heterocyclic compounds, etc., can solve the problems of lack of radical cure methods, and achieve the effect of improving immune indicators and rapid absorption

Inactive Publication Date: 2005-01-12
SUNSTONE TANGSHAN PHARM CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the treatment of venereal diseases, the use of antibiotics has a good effect on venereal diseases caused by bacteria such as gonorrhea, nongonococca...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation of valvciclovir HCL and Pidotimod

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0020] Examples see the table below

[0021] Table 1 Example

[0022]

[0023] Further illustrate the effect of the compound preparation of the present invention below by curative effect report.

[0024] Report on Curative Effect of Compound Preparation of Valaciclovir Hydrochloride and Pidotimod in Treatment of Condyloma Acuminatum

[0025] Condyloma acuminatum is a common sexually transmitted disease caused by human papillomavirus, and its incidence is on the rise. According to incomplete statistics, in 1999, condyloma acuminata accounted for 20-31% of sexually transmitted diseases. Using valaciclovir hydrochloride and pidotimod compound preparation of the present invention to treat patients with condyloma acuminatum, the results are as follows: Purpose: To observe the clinical remission rate of valaciclovir hydrochloride and pidotimod compound preparation for patients with condyloma acuminata

[0026] method:

[0027] 1. Cases: 40 outpatients diagn...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A compound medicine for treating venereal disease is prepared from Wannailuowei hydrochloride and Piduomode.

Description

technical field [0001] The invention relates to a compound preparation of valaciclovir hydrochloride and pidotimod for treating venereal diseases. Background technique [0002] In recent years, STDs have been prevalent in a large area in my country, with an average annual growth rate of 19.30% from 1991 to 2001. In the past two years, there has also been a growing trend. In the treatment of venereal diseases, the use of antibiotics has a good effect on venereal diseases caused by bacteria such as gonorrhea, nongonococcal urethritis, and syphilis; but there is still no effective cure for venereal diseases caused by viruses such as condyloma acuminata and genital herpes means. [0003] Valaciclovir is more common among clinically used antiviral drugs. Valaciclovir is the precursor of acyclovir, which is hydrolyzed into acyclovir in the body to inhibit the virus. It has a strong inhibitory effect on herpes simplex virus I (HSV-I) and herpes simplex virus II (HSV-II), and also...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/522A61K38/05A61P31/22
Inventor 韩志强贾晓冬
Owner SUNSTONE TANGSHAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap